Anticoagulants fail to prevent unexplained strokes, clinical trial finds

Anticoagulants fail to prevent unexplained strokes, clinical trial finds

Anticoagulants fail to prevent unexplained strokes
Visual Abstract. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy. Credit: JAMA, (2024). doi:10.1001/jama.2023.27188

A common practice of prescribing anticoagulants to people who have had unexplained strokes should stop, according to a study led by researchers at Columbia, Weill Cornell Medicine, and the University of Washington and published in JAMA.

Anticoagulants were thought to prevent additional strokes in people whose initial stroke has an unknown cause but who have a heart condition, atrial cardiopathy, that resembles atrial fibrillation, a common cause of stroke.

“We know these drugs work for people with atrial fibrillation, so we thought that they might probably work for people with atrial cardiopathy as well,” says Mitchell Elkind, MD, professor of neurology at the Vagelos College of Physicians and Surgeons and one of the study’s leaders. “That was the basis for the trial.”

However, the trial of 1,015 people found that patients with atrial cardiopathy who were given the anticoagulant apixaban had the same stroke rate, 4.4%, as patients who were given aspirin, the current standard of care.

“It’s disappointing as a physician-scientist to not have your hypothesis proven, but this study is still providing really useful information,” Elkind says. “It tells neurologists that patients with this type of heart condition, atrial cardiopathy, should not get anticoagulants, which are riskier than aspirin and should be reserved for people with definitive evidence of atrial fibrillation.”

The mystery of unexplained strokes

One-third of strokes have unknown causes, a challenge for neurologists trying to help their patients avoid subsequent strokes.

“We know what to do with people who have : We put them on anticoagulants to prevent clots. We know what to do with people who have a blockage in the : We operate to open the artery,” says Elkind. “But for one in three people whose stroke is unexplained, there’s always been uncertainty.”

Based on years of research, Elkind and a group of neurologists, including Hooman Kamel from Weill Cornell Medicine and colleagues from the University of Washington, thought they had found an answer: Many people who have unexplained strokes have changes in their heart that resemble changes seen in AFib.

Since these atrial changes appear to trigger clots like AFib, and anticoagulants successfully reduce stroke in patients with AFib, anticoagulants should also work to reduce clots and second strokes in patients with atrial cardiopathy.

Several backed the idea, with the strongest data coming from a large stroke prevention study led by Columbia’s J.P. Mohr in the 90s. An analysis of the stored blood samples from that study showed that anticoagulants were associated with fewer strokes in patients with biomarkers for atrial cardiopathy but not in other patients with unexplained strokes.

For several physicians, the idea was compelling, even without evidence from a prospective, randomized trial. “If you believed that your patient’s unexplained stroke really came from an embolism from the heart, the idea that you should prescribe anticoagulants was hard to shake,” Elkind says. “And so a lot of people were using them.”

The right treatment for the wrong patients?

Elkind and Kamel say there are several possible reasons why the trial did not support their hypothesis, including that they tested the right treatment in the wrong patients.

“In my mind, the next step is not to throw away the concept of treating atrial cardiopathy,” Elkind says, “but to see if there are indicators that do a better job at identifying patients who might benefit from .”

The trial included patients who had one of three biomarkers of atrial cardiopathy, all of which had been associated with the risk of , but the condition is not yet well-defined, and other biomarkers exist.

Another possibility is that other factors, including atherosclerosis, smoking, or , were responsible for the unexplained strokes of the participants. If so, targeting atrial cardiopathy might not have a big impact in preventing subsequent strokes.

The researchers are now discussing the next steps, including the feasibility of future trials. “We need to know how several patients can really benefit. Is it such a small proportion of patients we mightn’t be able to recruit enough patients?” Elkind says.

“I’d like to think that we just took a half step in the wrong direction, and we just need to continue in a slightly different direction to identify the right population of patients, so those are the kinds of questions we still need to answer.”

More information:
Hooman Kamel et al, Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial, JAMA, (2024). DOI: 10.1001/jama.2023.27188

Anticoagulants fail to prevent unexplained strokes, clinical trial finds (2024, February 7)
retrieved 7 February 2024

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Disasters Expo USA, is proud to be supported by Inergency for their next upcoming edition on March 6th & 7th 2024!

The leading event mitigating the world’s most costly disasters is returning to the Miami Beach

Convention Center and we want you to join us at the industry’s central platform for emergency management professionals.
Disasters Expo USA is proud to provide a central platform for the industry to connect and
engage with the industry’s leading professionals to better prepare, protect, prevent, respond
and recover from the disasters of today.
Hosting a dedicated platform for the convergence of disaster risk reduction, the keynote line up for Disasters Expo USA 2024 will provide an insight into successful case studies and
programs to accurately prepare for disasters. Featuring sessions from the likes of The Federal Emergency Management Agency,
NASA, The National Aeronautics and Space Administration, NOAA, The National Oceanic and Atmospheric Administration, TSA and several more this event is certainly providing you with the knowledge
required to prepare, respond and recover to disasters.
With over 50 hours worth of unmissable content, exciting new features such as their Disaster
Resilience Roundtable, Emergency Response Live, an Immersive Hurricane Simulation and
much more over just two days, you are guaranteed to gain an all-encompassing insight into
the industry to tackle the challenges of disasters.
By uniting global disaster risk management experts, well experienced emergency
responders and the leading innovators from the world, the event is the hub of the solutions
that provide attendees with tools that they can use to protect the communities and mitigate
the damage from disasters.
Tickets for the event are $119, but we have been given the promo code: HUGI100 that will
enable you to attend the event for FREE!

So don’t miss out and register today:

And in case you missed it, here is our ultimate road trip playlist is the perfect mix of podcasts, and hidden gems that will keep you energized for the entire journey


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More